Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients

American Journal of Psychiatry

Volumn 153, Issue 2, 1996, Pages 174-182

  Mann, J John ^a   Malone, Kevin M ^b   Diehl, David J ^b   Perel, James ^b   Cooper, Thomas B ^b   Mintun, Mark A ^b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECEPTOR SUBTYPE; SEROTONIN RECEPTOR;

ADULT; ARTICLE; BRAIN FUNCTION; BRAIN METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; FEMALE; GLUCOSE METABOLISM; HUMAN; IN VIVO STUDY; MALE; PRIORITY JOURNAL; SEROTONIN BRAIN LEVEL; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM;

EID: 0030048176     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.153.2.174     Document Type: Article

References (69)

1. Coppen AJ: Biochemical aspects of depression. Int Psychiatry Clin 1969; 6:53-81
2. Coppen A, Prange AH Jr, Hill C, Whybrow PC, Noguera R: Abnormalities of indoleamines in affective disorders. Arch Gen Psychiatry 1372; 26:474-478
3. Malone KM, Mann JJ: Serotonin and major depression, in Biology of Depressive Disorders, vol 3, part A: A System Perspective. Edited by Mann JJ, Kupfer DJ. New York, Plenum, 1993, pp 29-49
4. Lapin IP, Oxenkrug GF: Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1969; 1:132-136
5. Charney DS, Menkes DB, Heninger GR: Receptor sensitivity and the mechanism of action of antidepressant treatment: implications for the etiology and therapy of depression. Arch Gen Psychiatry 1981; 38:1160-1180
6. Shopsin B, Friedman E, Gershon S: Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. Arch Gen Psychiatry 1976; 33:811-819
7. Shopsin B, Gershon S, Goldstein M, Friedman E, Wilk S: Use of synthesis inhibitors in defining a role for biogenic amines during imipramine treatment in depressed patients. Psychopharmacology Communications 1975; 1(2):239-249
8. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR: Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990; 47:411-418
9. Young SN, Smith SE, Pihl RO, Ervin FR: Tryptophan depletion causes a rapid lowering of mood normal males. Psychopharmacology (Berl) 1985; 87:173-177
10. Upadhyaya AK, Pennell I, Cowen PJ, Deakin JFW: Blunted growth hormone and prolactin responses to L-tryptophan in depression: a state-dependent abnormality. J Affect Disord 1991; 21:213-218
11. Siever LJ, Murphy DL, Slater S, de la Vega E, Lipper S: Plasma prolactin changes following fenfluramine in depressed patients compared to controls: an evaluation of central serotonergic responsivity in depression. Life Sci 1984; 34:1029-1039
12. Coccaro EF, Siever LJ, Klar HM, Maurer G, Cochrane K, Cooper TB, Mohs RC, Davis KL: Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry 1989; 46:587-599; correction, 1990; 47:124
13. Mann JJ, McBride PA, Brown RP, Linnoila M, Leon AC, DeMeo MD, Mieczkowski T, Myers JE, Stanley M: Relationship between central and peripheral serotonin indexes in depressed and suicidal psychiatric inpatients. Arch Gen Psychiatry 1992; 49: 442-446
14. Golden RN, Hsiao JK, Lane E, Ekstrom D, Rogers S, Hicks R, Potter WZ: Abnormal neuroendocrine responsivity to acute iv clomipramine challenge in depressed patients. Psychiatry Res 1990; 31:39-47
15. Åsberg M, Bertilsson L, Martensson B, Scalia Tomba GP, Thorén P, Träskman-Bendz L: CSF monoamine metabolites in melancholia. Acta Psychiatr Scand 1984; 69:201-219
16. Åsberg M, Nordström P, Träskman-Bendz L: Cerebrospinal fluid studies in suicide: an overview. Ann NY Acad Sci 1986; 487:243-255
17. Åsberg M, Thorén P, Traskman L, Bertilsson L, Ringberger V: "Serotonin depression" - a biochemical subgroup within the affective disorders? Science 1976; 191:478-480
18. Gibbons RD, Davis JM: Consistent evidence for a biological subtype of depression characterized by low CSF monoamine levels. Acta Psychiatr Scand 1986; 74:8-12
19. Paasonen MK: Blood platelets as a model for aminergic neurons, in Proceedings of the 5th International Congress on Pharmacology, vol 4. Basel, Switzerland, Karger, 1973, pp 328-342
20. Kaplan RD, Mann JJ: Altered platelet serotonin uptake kinetics in schizophrenia and depression. Life Sci 1982; 3:583-588
21. Meltzer HY, Arora RC, Baber R, Tricou B-J: Serotonin uptake in blood platelets of psychiatric patients. Arch Gen Psychiatry 1981; 38:1322-1326
22. Scott M, Reading HW, London JB: Studies on human blood platelets in affective disorders. Psychopharmacology (Berl) 1979; 60:131-135
23. Biegon A, Grinspoon A, Blumenfeld B, Bleich A, Apter A, Mester R: Increased serotonin 5-HT2 receptor binding on blood platelets of suicidal men. Psychopharmacology (Berl) 1990; 100:165-167
24. Pandey GN, Pandey SC, Janicak PG, Marks RC, Davis JM: Platelet serotonin-2 receptor binding sites in depression and suicide. Biol Psychiatry 1990; 28:215-222
25. Mann JJ: Altered platelet monoamine oxidase activity in affective disorders. Psychol Med 1979; 9:729-736
26. Briley M: Imipramine binding: its relationship with serotonin uptake and depression, in Neuropharmacology of Serotonin. Edited by Green AR. Oxford, England, Oxford University Press, 1985, pp 50-78
27. Lewis DA, McChesney C: Tritiated imipramine binding distinguishes among subtypes of depression. Arch Gen Psychiatry 1985; 42:485-488
28. Mann JJ, Malone KM, Diehl DJ, Perel J, Nichols TE, Mintun MA: PET imaging of serotonin activation effects on prefrontal cortex in healthy volunteers. J Cereb Blood Flow Metab (in press)
29. Mann JJ, McBride PA, Malone KM, DeMeo MD, Keilp J: Blunted serotonergic responsivity in depressed patients. Neuropsychopharmacology 1995; 13:53-64
30. Coccaro EF, Kavoussi RJ, Hauger R: PRL responses to d-fenfluramine and D,L-fenfluramine in man, in Abstracts of the 32nd Annual Meeting of the American College of Neuropsychiatry. Nashville, Tenn, ACNP, 1993, p 160
31. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M: The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977; 28:897-916
32. Sokoloff L: Local cerebral energy metabolism: its relationship to local functional activity and blood flow, in Cerebral Vascular Smooth Muscle and Its Control. New York, Elsevier/North Holland, 1978, pp 171-197
33. Woods RP, Cherry SR, Mazziotta JC: Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr 1992; 16:620-633
34. Talairach J, Tournoux P: Co-Planar Stereotaxic Atlas of the Human Brain. New York, Thieme Medical, 1988, pp 1-122
35. Friston KJ, Worsley KJ, Frackowiak RSJ, Mazziotta JC, Evans AC: Assessing the significance of focal activations using their spatial extent. Human Brain Mapping 1994; 1:210-220
36. Spitzer RL, Williams JBW, Gibbon M, First MD: Structured Clinical Interview for DSM-III-R - Patient Version (SCID-P). New York, New York State Psychiatric Institute, Biometrics Research, 1989
37. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
38. McBride PA, Tierney H, DeMeo M, Chen J-S, Mann JJ: Effects of age and gender on CNS serotonergic responsivity in normal adults. Biol Psychiatry 1990; 27:1143-1155
39. Krebs HA, Cheng LK, Wright GJ: Determination of fenfluramine and norfenfluramine in plasma using a nitrogen-sensitive detector. J Chromatogr Biomed Appl 1984; 310:412-417
40. Myers JE, Mieczkowski TA, Perel J, Abbondanza DM, Cooper TB, Mann JJ: Abnormal behavioral responses to fenfluramine in patients with affective and personality disorders: correlation with increased serotonergic responsivity. Biol Psychiatry 1994; 35:112-120
41. McBride PA, Anderson GM, Hertzig ME, Sweeney JA, Kream J, Cohen DJ, Mann JJ: Serotonergic responsivity in male young adults with autistic disorder: results of a pilot study. Arch Gen Psychiatry 1989; 46:213-221; correction, 46:400
42. Friston KJ, Frith CD, Liddle PF, Frackowiak RSJ: Comparing functional (PET) images: the assessment of significant change. J Cereb Blood Flow Metab 1991; 11:690-699
43. Shook BL, Schlag-Rey M, Schlag J: Primate supplementary eye field, II: comparative aspects of connections with the thalamus, corpus striatum, and related forebram nuclei. J Comp Neurol 1991; 307:562-583
44. Buchsbaum MS, DeLisi LE, Holcomb HH, Cappelletti J, King AC, Johnson J, Hazlett E, Dowling-Zimmerman S, Post RM, Morihisa J, Carpenter W, Cohen R, Pickar D, Weinberger DR, Margolis R, Kessler RM: Anteroposterior gradients in cerebral glucose use in schizophrenia and affective disorders. Arch Gen Psychiatry 1984; 41:1159-1166
45. HT1A binding sites in frontal cortex of suicide victims. J Neural Transm 1991; 85:181-194
46. 11C-Glucose metabolism in manic and depressed patients. Psychiatry Res 1987; 22:81-88
47. Martinot J-L, Hardy P, Feline A, Huret J-D, Mazoyer B, Attar-Levy D, Pappata S, Syrota A: Left prefrontal glucose hypometabolism in the depressed state: a confirmation. Am J Psychiatry 1990; 147:1313-1317
48. Biver F, Goldman S, Delvenne V, Luxen A, DeMaertelaer V, Hubain P, Mendlewicz J, Lotstra F: Frontal and parietal metabolic disturbances in unipolar depression. Biol Psychiatry 1994; 36: 381-388
49. Cohen RM, Semple WE, Gross M, Nordahl TE, King AC, Picker D, Post RM: Evidence for common alterations in cerebral glucose metabolism in major affective disorders and schizophrenia. Neuropsychopharmacology 1989; 2:241-254
50. Baxter LR Jr, Schwartz JM, Phelps ME, Mazziotta JC, Guze BH, Selin CE, Gerner RH, Sumida RM: Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry 1989; 46:243-250
51. 99mTc-exametazime in major depression and the pattern of brain activity underlying the psychotic/neurotic continuum. J Affect Disord 1992; 26:31-43
52. Post RM, DeLisi LE, Holcomb HH, Uhde TW, Cohen R, Buchsbaum MS: Glucose utilization in the temporal cortex of affectively ill patients: positron emission tomography. Biol Psychiatry 1987; 22:545-553
53. 18F]2-deoxyglucose in affective illness. J Affect Disord 1986; 10:137-152
54. Baxter LR Jr, Phelps ME, Mazziotta JC, Schwartz JM, Gerner RH, Selin CE, Sumida RM: Cerebral metabolic rates for glucose in mood disorders: studies with positron emission tomography and fluorodeoxyglucose F 18. Arch Gen Psychiatry 1985; 42: 441-447
55. Wu JC, Gillin JC, Buchsbaum MS, Hershey T, Johnson JC, Bunney WE Jr: Effect of sleep deprivation on brain metabolism of depressed patients. Am J Psychiatry 1992; 149:538-543
56. Aghajanian GK, Sprouse JS, Sheldon P, Rasmussen K: Electrophysiology of the central serotonin system: receptor subtypes and transducer mechanisms. Ann NY Acad Sci 1990; 600:93-103
57. Crane PD, Braun LD, Cornford EM, Cremer JE, Glass JM, Oldendorf WH: Dose dependent reduction of glucose utilization by pentobarbital in rat brain. Stroke 1978; 9:12-18
58. + transport in canine brain. Stroke 1981; 12:726-730
59. Schwartz JM, Baxter LR, Mazziotta JC, Gerner RH, Phelps ME: The differential diagnosis of depression: relevance of positron emission tomography studies of cerebral glucose metabolism to the bipolar-unipolar dichotomy. JAMA 1987; 258:1368-1374
60. Mata M, Fink DJ, Gainer H, Smith CB, Davidsen L, Savaki H, Schwartz WJ, Sokoloff L: Activity-dependent energy metabolism in rat posterior pituitary primarily reflects sodium pump activity. J Neurochem 1980; 34:213-215
61. Freo U, Soncrant TT, Ricchieri GL, Wozniak KM, Larson DM, Rapoport SI: Time courses of behavioral and regional cerebral metabolic responses to different doses of meta-chlorophenylpiperazine in awake rats. Brain Res 1990; 511:209-216
62. Freo U, Pietrini P, Dam M, Pizzolato G, Battistin L: The tricyclic antidepressant clomipramine dose-dependently reduces regional cerebral metabolic rates for glucose in awake rats. Psychopharmacology (Berl) 1993; 113:53-59
63. 1A partial agonists gepirone, ipsapirone and buspirone on local cerebral glucose utilization in the conscious rat. Psychopharmacology (Berl) 1992; 106:97-101
64. Freo U, Ricchieri GL, Holloway HW, Soncrant TT: Time- and dose-dependent effects of the serotonergic agent quipazine on regional cerebral metabolism in rats. Brain Res 1993; 600:249-256
65. Freo U, Holloway HW, Kalogeras K, Rapoport SI, Soncrant TT: Adrenalectomy or metyrapone-pretreatment abolishes cerebral metabolic responses to the serotonin agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) in the hippocampus. Brain Res 1992; 586:256-264
66. Sackeim HA, Greenberg MS, Weiman AL, Gur RC, Hungerbuhler JP, Geschwind N: Hemispheric asymmetry in the expression of positive and negative emotions. Arch Neurol 1982; 39:210-218
67. Robinson RG, Kubos KL, Starr LB, Rao K, Price TR: Mood disorders in stroke patients: importance of location of lesion. Brain 1984; 107:81-93
68. Starkstein SE, Robinson RG, Price TR: Comparison of cortical and subcortical lesions in the production of poststroke mood disorders. Brain 1987; 110:1045-1059
69. Starkstein SE, Robinson RG, Berthier ML, Price TR: Depressive disorders following posterior circulation as compared with middle cerebral artery infarcts. Brain 1988; 111:375-387